Our team
Karolinska Development’s team has extensive experience of managing life science investments in a listed environment. Our employees’ day-to-day work involves ensuring that the portfolio companies have optimum value generation strategies, have sufficient resources to implement these strategies, and have world-leading expertise in business development and the scientific areas in which they operate.
Viktor Drvota
Viktor Drvota
Chief Executive Officer
Appointed as CEO on June 1, 2017 succeeding Jim Van heusden, and previously CIO since 2016.
Born 1965. M.D, Ph.D. Associate Prof. In Cardiology.
Viktor Drvota has over 20 years of Venture Capital experience with several investements, significant fundraisings, IPOs and exits. He was responsible for Life science at SEB Venture Capital 2002-2016. During his appointment at SEB VC he also served as a Board member in several biotech and Medtech companies such as Arexis AB, SBL Vaccin AB, Nuevolution AS, Index Pharma AB, Scibase AB, Airsonett AB among others. Before joining SEB in, Dr Drvota worked as Senior Consultant and Associate Professor in Cardiology at the Karolinska Institutet/hospital, Stockholm. Dr Drvota has experience from preclinical as well as clinical research in drug development and medical devices. Dr Drvota has 29 published research articles.
Holdings in Karolinska Development: 209,996 shares.
Appointed as CEO on June 1, 2017 succeeding Jim Van heusden, and previously CIO since 2016.
Born 1965. M.D, Ph.D. Associate Prof. In Cardiology.
Viktor Drvota has over 20 years of Venture Capital experience with several investements, significant fundraisings, IPOs and exits. He was responsible for Life science at SEB Venture Capital 2002-2016. During his appointment at SEB VC he also served as a Board member in several biotech and Medtech companies such as Arexis AB, SBL Vaccin AB, Nuevolution AS, Index Pharma AB, Scibase AB, Airsonett AB among others. Before joining SEB in, Dr Drvota worked as Senior Consultant and Associate Professor in Cardiology at the Karolinska Institutet/hospital, Stockholm. Dr Drvota has experience from preclinical as well as clinical research in drug development and medical devices. Dr Drvota has 29 published research articles.
Holdings in Karolinska Development: 209,996 shares.
Johan Dighed
Johan Dighed
Chief Legal Officer and Deputy CEO
Appointed Chief Legal Officer 2020 and Deputy CEO 2021
Born 1973. Master of Laws.
Johan Dighed has over 20 years’ experience in financial and business law including positions as Head of Legal with the German bank SEB AG and legal counsel with SEB AB. Prior to joining the financial sector he worked with the international law firm Baker & McKenzie and in the Swedish Judiciary.
Holdings in Karolinska development: 400,192 shares.
Appointed Chief Legal Officer 2020 and Deputy CEO 2021
Born 1973. Master of Laws.
Johan Dighed has over 20 years’ experience in financial and business law including positions as Head of Legal with the German bank SEB AG and legal counsel with SEB AB. Prior to joining the financial sector he worked with the international law firm Baker & McKenzie and in the Swedish Judiciary.
Holdings in Karolinska development: 400,192 shares.
Hans Christopher ”HC” Toll
Hans Christopher ”HC” Toll
Chief Financial Officer
Appointed 2022.
Born 1968. MSc in Business and Economics.
HC Toll has more than 25 years of experience as business controller and CFO, in different industries, both in Sweden and internationally. HC has i.a. been CFO in AIK Fotboll AB and QuiaPEG AB. HC is since 2021 part time CFO in the KD portfolio company Umecrine Cognition AB.
In addition to life science, HC has experience in a range of industries, such as heavy manufacturing, retail, gaming, etc.
Holdings in Karolinska development: 35,000 shares.
Appointed 2022.
Born 1968. MSc in Business and Economics.
HC Toll has more than 25 years of experience as business controller and CFO, in different industries, both in Sweden and internationally. HC has i.a. been CFO in AIK Fotboll AB and QuiaPEG AB. HC is since 2021 part time CFO in the KD portfolio company Umecrine Cognition AB.
In addition to life science, HC has experience in a range of industries, such as heavy manufacturing, retail, gaming, etc.
Holdings in Karolinska development: 35,000 shares.
John Öhd
John Öhd
Chief Scientific Officer/Venture Partner
Appointed 2020
Born 1971, M.D., Ph.D. John has broad knowledge and experience of drug development in several therapeutic areas, including CNS, cancer and blood disorders. He has held leadership roles within the research organizations of AstraZeneca, Shire Pharmaceuticals and Medivir. Before joining Karolinska Development he was the Chief Medical Officer of Modus Therapeutics. Prior to his drug development roles, John held various research and clinical positions at Lund University and Karolinska Institutet/University Hospital.
No holdings in Karolinska Development.
Appointed 2020
Born 1971, M.D., Ph.D. John has broad knowledge and experience of drug development in several therapeutic areas, including CNS, cancer and blood disorders. He has held leadership roles within the research organizations of AstraZeneca, Shire Pharmaceuticals and Medivir. Before joining Karolinska Development he was the Chief Medical Officer of Modus Therapeutics. Prior to his drug development roles, John held various research and clinical positions at Lund University and Karolinska Institutet/University Hospital.
No holdings in Karolinska Development.
Elisabet Gimbringer
Elisabet Gimbringer
Financial Manager
Employed since November 2015. Born 1965. Economics and Business education from Stockholm University. Elisabet has worked as an approved public accountant for 10 years, and as a financial manager, business controller and financial controller for a number of different companies and fields for the last 20 years.
Holdings in Karolinska Development: 30,000 shares.
Employed since November 2015. Born 1965. Economics and Business education from Stockholm University. Elisabet has worked as an approved public accountant for 10 years, and as a financial manager, business controller and financial controller for a number of different companies and fields for the last 20 years.
Holdings in Karolinska Development: 30,000 shares.
Eva Montgomerie
Eva Montgomerie
Head of Accounting
Employed since October 2013, employed within the group since 2007.
Born 1958. MSc in Business and Economics.
Eva Montgomerie has worked within the bank and finance sector for 12 years, 10 years within the food and clothing sector and 10 years within life science.
Other appointments: Finance manager in Dilafor AB and Pharmanest AB.
Holdings in Karolinska Development: 23,865 shares.
Employed since October 2013, employed within the group since 2007.
Born 1958. MSc in Business and Economics.
Eva Montgomerie has worked within the bank and finance sector for 12 years, 10 years within the food and clothing sector and 10 years within life science.
Other appointments: Finance manager in Dilafor AB and Pharmanest AB.
Holdings in Karolinska Development: 23,865 shares.
Mikaela Sörman
Mikaela Sörman
Investment Manager
Born 1990. M.Sc. in Public Health & Health Inequalities
Mikaela Sörman has 9 years experience from the health care industry. Before joining Karolinska Development she worked at Boston Consulting Group, a management consultancy firm, where she focused exclusively on MedTech and Life Science projects. Mikaela also holds experience from project management after working several years in a health care social start-up, Stiftelsen Choice.
Holdings in Karolinska Development: 10,003 shares.
Born 1990. M.Sc. in Public Health & Health Inequalities
Mikaela Sörman has 9 years experience from the health care industry. Before joining Karolinska Development she worked at Boston Consulting Group, a management consultancy firm, where she focused exclusively on MedTech and Life Science projects. Mikaela also holds experience from project management after working several years in a health care social start-up, Stiftelsen Choice.
Holdings in Karolinska Development: 10,003 shares.
